How glucose, A1C, islet autoantibodies, C-peptide, and ketones help clarify diabetes type, remaining insulin production, and urgent risk.
Adult-onset type 1 diabetes can initially resemble type 2 diabetes. In a slower-progressing presentation often called latent autoimmune diabetes in adults, or LADA, the pancreas may continue producing insulin for a time. That remaining production can make the diagnosis less obvious.
Autoantibodies and C-peptide tests answer different questions. Islet autoantibodies provide evidence of an autoimmune process. C-peptide helps assess the body's own insulin production. A1C and plasma glucose establish the glycemic picture, while ketones can identify an urgent consequence of insulin deficiency. A clinician selects and interprets these tests according to the person's symptoms, treatment, and clinical course; everyone does not need every test.
Seek emergency care for possible diabetic ketoacidosis: repeated vomiting, severe abdominal pain, deep or rapid breathing, confusion, unusual drowsiness, or inability to keep fluids down, especially with elevated glucose or ketones. Do not wait for routine laboratory results. Suspected insulin deficiency needs prompt assessment even before the diabetes type is fully classified.
For the broader testing framework, visit Diabetes and Prediabetes Blood Tests. For help understanding report flags, units, reference intervals, and trends, see How to Read and Understand Your Lab Results.
Autoimmune type 1 diabetes develops when the immune system targets pancreatic beta cells, reducing their ability to make insulin. It can begin at any age. Some adults lose insulin production quickly; others progress gradually and may initially respond to medicines usually used for type 2 diabetes.
LADA describes a slower course of autoimmune diabetes beginning in adulthood. The ADA includes it within type 1 diabetes. The informal term “type 1.5 diabetes” should not suggest that it is a separate halfway category. Some people with autoimmune diabetes also have obesity or insulin resistance, and some people with type 2 diabetes are lean. Body size alone cannot determine the diagnosis. [1]
A classification review becomes especially useful when the clinical course differs from what the original diagnosis would predict. Reasons to discuss autoimmune testing include:
These findings support evaluation; none proves LADA by itself. Medication effects, pancreatic disease, monogenic diabetes, and other causes can produce atypical presentations. Treatment of dangerous hyperglycemia or insulin deficiency must proceed while classification is being clarified. The Prediabetes and Type 2 Diabetes testing guide explains the broader type 2 pathway.
| Clinical question | Relevant tests | Interpretation boundary |
|---|---|---|
| Is glucose regulation abnormal? | Hemoglobin A1C, plasma glucose, and selected oral glucose tolerance testing. | They assess glycemia and support diagnosis when criteria are met; they do not establish autoimmune cause. |
| Is pancreatic autoimmunity present? | GAD65, IA-2, ZnT8, and selected insulin autoantibody testing. | Results require clinical context, assay interpretation, and appropriate confirmation. |
| How much insulin is the pancreas producing? | C-peptide with concurrent glucose. | Meal timing, kidney function, disease duration, and recent metabolic instability affect interpretation. |
| Could insulin deficiency be causing an emergency? | Blood beta-hydroxybutyrate or urine ketones, together with acute-care testing. | Ketones do not establish the diabetes type. Suspected DKA requires emergency evaluation. |
Plasma glucose measures the level at collection. Hemoglobin A1C reflects glucose exposure over roughly the preceding two to three months. A clinician may use an oral glucose tolerance test when a glucose challenge can resolve a defined question.
In nonpregnant adults, standard diabetes criteria include A1C of at least 6.5%, fasting plasma glucose of at least 126 mg/dL, a two-hour glucose of at least 200 mg/dL during a 75-gram OGTT, or random plasma glucose of at least 200 mg/dL with classic symptoms or a hyperglycemic crisis. Without unequivocal hyperglycemia, diagnosis generally requires confirmation. [1]
A1C can lag a rapid deterioration and can be misleading when red-cell turnover or hemoglobin abnormalities alter its relationship with glucose. A reassuring A1C should not dismiss significant symptoms or an abnormal current glucose. Continuous glucose monitoring and home meters help guide care, but they do not replace accepted laboratory diagnostic criteria. For more context, see The Complete Guide to Lab Tests and Blood Work.
The Glutamic Acid Decarboxylase-65 Antibody Test looks for an immune response against GAD65. In an adult whose presentation suggests type 1 diabetes, the ADA classification pathway prioritizes GAD antibody testing. A positive result supports an autoimmune cause when it fits the clinical picture.
An isolated weak positive is less convincing when the likelihood of autoimmune disease was low before testing. The laboratory's method, reference limits, the person's history, and other findings matter. Antibody concentration is not a measure of daily insulin requirements.
If GAD65 is negative but suspicion remains, an IA-2 Antibody Test and/or Zinc Transporter 8 Antibody Test may provide additional information. A negative GAD65 result alone does not close the evaluation. Some people with clinical type 1 diabetes have no detectable islet autoantibodies, and antibody detection can change with disease duration.
A Diabetes Type 1 Autoantibody Screening Panel can be considered when a clinician wants several markers assessed together. Review the current panel components and treatment history before ordering; a panel name does not establish that it answers every classification or screening question.
An Insulin Autoantibody Test can help before exposure to injected insulin. After insulin treatment begins, antibodies may arise in response to treatment, making the result less useful for identifying the original cause of diabetes. Record the treatment history, and never delay necessary insulin to obtain an antibody sample.
Screening a person without overt diabetes is different from classifying someone who already has hyperglycemia. In presymptomatic screening, a positive antibody result needs confirmation and a metabolic evaluation. Multiple confirmed antibodies increase concern, but a single result should not simply be dismissed: ADA guidance gives particular attention to a single confirmed IA-2 antibody. These findings call for a follow-up plan, not interpretation from a laboratory flag alone. [1]
The pancreas releases C-peptide when it produces insulin. Injected insulin does not contain C-peptide, so the C-Peptide Test can help assess endogenous insulin production. In the ADA adult classification algorithm, it is used selectively in people receiving insulin whose diabetes type needs clarification. Other specialist indications exist, but it is not a universal diabetes screening test.
Always read C-peptide with the glucose collected at the same time. A low value during hypoglycemia may reflect an appropriate reduction in insulin secretion. A similarly low value while glucose is elevated raises a different concern. Kidney impairment can raise circulating C-peptide by reducing clearance.
Also record fasting or meal status, medicines, time since diagnosis, and recent illness. Preserved C-peptide can occur early in autoimmune disease, including during partial remission. Low C-peptide can occur in longstanding type 2 diabetes or pancreatic disorders. Neither pattern establishes the cause on its own.
For its classification pathway, the ADA allows a random C-peptide sample with concurrent glucose within five hours of eating in place of formal stimulation testing. This is not a universal preparation instruction for every C-Peptide order. A laboratory or product may specify fasting. Confirm the intended protocol with the ordering clinician and laboratory before collection, and follow the requirements for the actual order. Do not improvise a meal challenge or adjust insulin on your own to prepare for testing.
Do not measure C-peptide for this classification purpose within two weeks of a hyperglycemic emergency. Acute metabolic disturbance can make the result misleading. This timing rule concerns later classification; it must not delay emergency treatment. [1]
| C-peptide result | Possible meaning in the appropriate context |
|---|---|
| At least 600 pmol/L, approximately 1.8 ng/mL | Substantial endogenous insulin production remains. This can support reconsidering classification but does not independently exclude early autoimmune diabetes. |
| 200 to below 600 pmol/L, approximately 0.6 to below 1.8 ng/mL | An overlapping range seen in type 1 diabetes, some monogenic diabetes, and some insulin-treated type 2 diabetes. |
| Very low, such as below 80 pmol/L, approximately 0.24 ng/mL | Strong evidence of severe insulin deficiency in the relevant clinical setting. |
These are selected decision aids, not a complete classification system or universal laboratory reference intervals. Values outside the listed examples still require interpretation. When a result is below 600 pmol/L and the concurrent glucose is below 70 mg/dL, or the person may have been fasting, the clinician may consider repeating it under appropriate conditions.
Detectable C-peptide is not permission to stop insulin. If a clinician is considering insulin withdrawal in an insulin-treated person whose diabetes type is uncertain, C-peptide should first help exclude severe insulin deficiency. Any change still requires an individualized treatment plan.
Yes. Autoimmune activity can precede overt hyperglycemia. Presymptomatic screening is particularly relevant to people with a family history of type 1 diabetes or otherwise known elevated genetic risk. It requires planned confirmation, education, and follow-up.
| Stage | Core pattern | What follows |
|---|---|---|
| Stage 1 | Two or more confirmed islet autoantibodies with normal glycemia. | Specialist-directed monitoring and education about progression and symptoms. |
| Stage 2 | Islet autoantibodies, usually multiple, with dysglycemia below overt diabetes thresholds. | Formal metabolic staging and discussion of monitoring, trials, or an approved treatment when eligible. |
| Stage 3 | Diabetes meeting standard diagnostic criteria. Symptoms may be present, although surveillance can identify progression before symptoms are recognized. | Prompt clinical assessment and treatment appropriate to insulin deficiency and the person's condition. |
A normal glucose result does not erase confirmed islet autoimmunity. Conversely, one positive antibody does not automatically establish Stage 1 or treatment eligibility. Confirmation, antibody type, glycemia, and follow-up determine the next step. [1]
The FDA expanded teplizumab-mzwv, marketed as Tzield, on April 20, 2026, to delay Stage 3 onset in adults and children age one year and older with Stage 2 type 1 diabetes. On June 12, 2026, it granted a separate accelerated approval for recently diagnosed Stage 3 disease in ages 8–17, aimed at slowing loss of endogenous insulin production. The pediatric Stage 3 indication is not an adult LADA treatment indication. [5]
For Stage 2 treatment, the label requires at least two positive islet autoantibodies and documented dysglycemia without overt hyperglycemia. It notes limited evidence in adults age 45 and older. The pediatric Stage 3 approval used reduced C-peptide decline as a surrogate endpoint, with confirmatory evidence required.
Specialist selection, pretreatment safety assessment, and monitoring are essential. The June 2026 label includes a boxed warning about serious viral reactivation. An antibody result alone cannot establish eligibility or replace insulin when insulin is needed. [6]
Ketones become particularly important when insufficient insulin is accompanied by illness, vomiting, sustained hyperglycemia, missed insulin, or a pump-delivery problem. The Beta-Hydroxybutyrate Test measures the predominant ketone in DKA. Urine ketones can lag behind changes in blood ketones.
DKA requires assessment of ketosis and metabolic acidosis in a diabetes or hyperglycemia context. High glucose alone does not diagnose it, and glucose that is not markedly elevated does not exclude it, particularly with SGLT2 inhibitor exposure. A positive ketone result also does not prove that the underlying diabetes is autoimmune.
Follow a clinician-provided sick-day plan and seek emergency care for the warning signs described above. Home testing and routine outpatient collection cannot replace assessment of acid-base status, electrolytes, dehydration, and clinical stability. For the detailed explanation, read Diabetic Ketoacidosis and Ketone Testing. [4]
Autoimmune conditions can occur together. Testing should follow the relevant screening recommendation or a specific clinical question.
Avoid assuming every episode of fatigue, digestive symptoms, or neuropathy comes from diabetes. Equally, an autoimmune diabetes diagnosis does not justify ordering an unrestricted autoimmune or nutrient panel. [2]
| Pattern | Interpretation and next question |
|---|---|
| Hyperglycemia, positive islet antibodies, and preserved C-peptide | Early or slowly progressive autoimmune diabetes remains possible. How will glucose and insulin needs be monitored? |
| Hyperglycemia, positive antibodies, and low C-peptide | Autoimmune diabetes with reduced insulin production is supported. Are symptoms or ketones creating an urgent safety issue? |
| Negative GAD65 but a strongly suggestive clinical course | Review other antibodies and alternative causes. Was the evaluation sufficiently broad and appropriately timed? |
| Negative antibodies and low C-peptide | Insulin deficiency may be present despite an uncertain cause. Consider disease duration, pancreatic disease, and antibody-negative type 1 diabetes. |
| Multiple confirmed antibodies with normal glycemia | Presymptomatic disease requires a staging and monitoring plan; normal glucose does not end follow-up. |
| Ketones with vomiting, deep breathing, or confusion | Possible DKA requires emergency assessment before further outpatient classification. |
These examples illustrate questions, not diagnostic formulas. Review the full report, collection conditions, clinical history, and current treatment.
Classification and routine monitoring serve different purposes. Islet antibodies mainly support autoimmune classification or presymptomatic risk assessment. C-peptide is repeated when a meaningful question about insulin production or classification remains. Neither should automatically become a quarterly test for everyone with LADA.
After diagnosis, follow-up focuses on glucose patterns, hypoglycemia, treatment effectiveness, and complication prevention. A1C is commonly assessed at least twice yearly when stable and at goal, and approximately every three months when treatment changes or goals are not met. CGM or meter information adds detail that an average cannot show. [3]
Kidney assessment, urine albumin, lipid testing, and associated-condition testing follow diabetes duration, symptoms, prior findings, and the care plan. Eye, foot, blood-pressure, and medication reviews remain necessary even when laboratory results appear reassuring. Presymptomatic antibody-positive people need their own monitoring schedule rather than automatically following an established-diabetes schedule.
Yes. Autoimmune beta-cell loss and insulin resistance can coexist. Weight should be considered with the clinical course and testing, not used to exclude autoimmune diabetes.
No. Insulin production may remain measurable early in the disease. Interpretation depends on concurrent glucose, collection conditions, kidney function, and antibody findings.
It supports an autoimmune explanation in the right setting but does not establish the entire diagnosis, disease stage, or treatment plan. A screening result may need confirmation and further metabolic assessment.
No. Ketones address acute risk and defined sick-day situations. They are not a routine requirement for classifying every stable adult.
Bring the specific clinical question to your healthcare professional: whether the diabetes could be autoimmune, whether insulin production needs clarification, or whether a related symptom needs investigation. Select tests around that question and arrange follow-up before collection.
Ulta Lab Tests offers access to relevant laboratory testing where available. Review current product components, preparation instructions, and eligibility before ordering. Learn more in Direct-Access Lab Testing: How It Works and What to Expect. Suspected type 1 diabetes, insulin changes, and treatment eligibility require qualified clinical care; possible DKA requires emergency evaluation.
This article provides laboratory education and does not replace individualized medical advice, diagnosis, or treatment.
Originally published: JULY 14 2026 | Updated: SEPTEMBER 18, 26, 2026
| Category | Tests |
|---|---|
| Autoimmune diabetes classification | GAD65 Antibody Test; IA-2 Antibody Test; Zinc Transporter 8 Antibody Test (ZnT8); Insulin Autoantibody Test; Diabetes Type 1 Autoantibody Screening Panel Test |
| Remaining insulin production | C-Peptide Test, interpreted with concurrent glucose |
| Glycemic status | A1c Test; Glucose Plasma Test; Glucose Random Test; Glucose Tolerance Test, 2 Specimens, 75 g |
| Ketones and acute risk | Beta-Hydroxybutyrate Test |
| Associated thyroid evaluation | TSH Test; Free T4 Test |
| Associated celiac evaluation | Tissue Transglutaminase IgA Antibody Test; Total IgA Test |
| B12 deficiency and anemia evaluation | Vitamin B12 Test; Complete Blood Count with Differential and Platelets; Methylmalonic Acid Test |
| Priority | Related Health Area | Connection |
|---|---|---|
| 1 | Diabetes Tests | Main testing health area |
| 2 | Autoimmune Tests | Autoimmune classification |
| 3 | Thyroid Tests | Associated thyroid evaluation |
| 4 | Digestive System Tests | Celiac disease and malabsorption |
| 5 | Vitamin & Mineral Tests | B12 and nutrient evaluation |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
